Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CTT Pharmaceuticals
Hamilton, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
CTT Pharmaceuticals has demonstrated in clinical research that its wafer enables dose-specific, fast drug delivery with rapid oral mucosal absorption—achieving 40% quicker and 28% higher peak THC blood levels versus edibles. A major nicotine cessation product is at the NIH grant proposal stage for clinical trial funding, and the opioid and cannabis wafer applications are at the licensing and development stage[2][5][1].
- Therapeutic areas
- RheumatologyNeurologyDermatologyPsychiatryOncology
- Modalities
- Small moleculeBiologicCannabinoidOpioidOral thin film
- Industry
- Biotech
02
Partnerships
Aurora Cannabis
Beyond the preview
Go deeper on CTT Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTT Pharmaceuticals.